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Abstract
Severe alpha-1 antitrypsin (AAT) deficiency is one of the most common serious
genetic diseases in adults of European descent. Individuals with AAT
deficiency have a greatly increased risk for emphysema and liver disease.
Other manifestations include bronchiectasis, necrotizing panniculitis and
granulomatosis with polyangiitis. Despite the frequency and potential severity,
AAT deficiency remains under-recognized, and there is often a delay in
diagnosis. This review will focus on three recent updates that should serve to
encourage testing and diagnosis of AAT deficiency: first, the publication of a
randomized clinical trial demonstrating the efficacy of intravenous
augmentation therapy in slowing the progression of emphysema in AAT
deficiency; second, the mounting evidence showing an increased risk of lung
disease in heterozygous PI MZ genotype carriers; last, the recent publication of
a clinical practice guideline, outlining diagnosis and management. Though it
has been recognized for more than fifty years, AAT deficiency exemplifies the
modern paradigm of precision medicine, with a diagnostic test that identifies a
genetic subtype of a heterogeneous disease, leading to a targeted treatment.
1
2
3
     Referee Status:
  Invited Referees
 version 1
published
27 Nov 2017
   1 2 3
, Hospital Universitari VallMarc Miravitlles
d'Hebron, Spain
1
, University of Leicester, UKBibek Gooptu2
, University ofElizabeth Sapey
Birmingham, UK
3
 27 Nov 2017,  (F1000 Faculty Rev):2049 (doi: First published: 6
)10.12688/f1000research.12399.1
 27 Nov 2017,  (F1000 Faculty Rev):2049 (doi: Latest published: 6
)10.12688/f1000research.12399.1
v1
Page 1 of 8
F1000Research 2017, 6(F1000 Faculty Rev):2049 Last updated: 27 NOV 2017
  Craig P. Hersh ( )Corresponding author: craig.hersh@channing.harvard.edu
  : Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & EditingAuthor roles: Hersh CP
 Dr. Hersh reports consulting fees from AstraZeneca, Mylan, Concert Pharmaceuticals, and 23andMe; grant support fromCompeting interests:
the Boehringer Ingelheim; and pending grant support from Novartis. Dr. Hersh is a member of the Grants Advisory Committee of the Alpha-1
Foundation.
 Hersh CP. How to cite this article: Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine [version 1; referees: 3
   2017,  (F1000 Faculty Rev):2049 (doi:  )approved] F1000Research 6 10.12688/f1000research.12399.1
 © 2017 Hersh CP. This is an open access article distributed under the terms of the  , whichCopyright: Creative Commons Attribution Licence
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 This work was funded by U.S. National Institutes of Health grants R01HL125583, R01HL130512, and P01HL105339. Grant information:
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 27 Nov 2017,  (F1000 Faculty Rev):2049 (doi:  ) First published: 6 10.12688/f1000research.12399.1
Page 2 of 8
F1000Research 2017, 6(F1000 Faculty Rev):2049 Last updated: 27 NOV 2017
Introduction
Severe alpha-1 antitrypsin (AAT) deficiency is one of the most 
common serious genetic diseases in adults of European descent, 
with an estimated prevalence of 1 in 1500 to 1 in 30001,2. The 
AAT protein, the major inhibitor of neutrophil elastase, is 
encoded by the SERPINA1 gene on chromosome 14 and secreted 
from the liver. Severe AAT deficiency is usually due to autosomal 
recessive inheritance of the PI*Z allele of SERPINA1, with the 
resulting PI ZZ genotype. Severe AAT deficiency is associated 
with an increased risk of emphysema, especially in cigarette 
smokers, due to the imbalance between proteases and anti-proteases 
in the lung tissue. The misfolded Z protein polymerizes in the liver, 
causing damage to hepatocytes and potentially leading to cirrhosis 
and hepatocellular carcinoma. Other conditions associated with 
AAT deficiency include bronchiectasis, necrotizing panniculitis 
and granulomatosis with polyangiitis.
Despite the high prevalence and potentially serious clinical 
manifestations, AAT deficiency remains under-recognized, and 
there is often a delay in diagnosis in symptomatic individuals, 
as long as five to eight years3,4. This review will focus on three 
recent updates that should serve to encourage testing and diagno-
sis of AAT deficiency, which is necessary to appropriately counsel 
patients and provide specific therapy. First is the publication of a 
randomized clinical trial demonstrating the efficacy of intrave-
nous augmentation therapy in slowing the progression of emphy-
sema in patients with chronic obstructive pulmonary disease 
(COPD) due to AAT deficiency5. Second is the mounting evidence 
showing an increased risk of airflow obstruction in heterozygous 
carriers (genotype PI MZ)6,7. Last is the recent publication of a 
clinical practice guideline outlining the diagnosis and management 
of AAT deficiency8. The full spectrum of the genetics, biology, 
and clinical manifestations of AAT deficiency has been reviewed 
elsewhere9–12.
Clinical trial of augmentation therapy
Augmentation therapy with intravenous infusion of pooled 
human AAT is available in North America and in several, but not 
all, European countries. Augmentation therapy was approved 
based on studies demonstrating biochemical efficacy13,14. Clinical 
use has been supported largely from observational and registry 
studies15–17. Two small randomized trials suggested a reduction in 
the loss of lung tissue on chest computed tomography scans18,19, 
which was statistically significant when the results were combined 
in a meta-analysis20.
These studies provided the background for the RAPID trial, a 
multicenter, double-blind, randomized controlled trial of intra-
venous AAT augmentation therapy5. Study subjects were former 
smokers ages 18–65 with severe AAT deficiency (<11 µM) and 
reduced lung function with a forced expiratory volume in 1 second 
(FEV1) of 35–70% predicted. 95 subjects received AAT infusions 
at a dose of 60 mg/kg weekly, and 87 subjects received placebo 
infusions. The primary endpoint was lung density on chest 
CT scans at total lung capacity (TLC) and functional residual 
capacity combined, over the two year trial. There was a 29% 
reduction in the change of combined lung density endpoint between 
the two arms, which was not statistically significant. However, 
the change in lung density at TLC was 34% lower in the AAT 
augmentation group (P = 0.03) (Figure 1). Lung density measure-
ments at full inspiration (i.e. TLC) are the clinical standard, may 
be subject to less noise21, and more closely reflect emphysema22,23. 
Emphysema progression as an endpoint is more specific to 
the disease pathology of AAT deficiency than FEV1 decline, a 
more commonly used outcome in COPD clinical trials. Augmen-
tation therapy could be considered as disease-modifying, and was 
estimated to prolong time to death or lung transplant by almost six 
years, based on post-hoc extrapolation5,24. There was no difference 
in change in lung function, exacerbations, exercise capacity, or 
quality of life between the treatment and placebo arms.
Following the two-year RAPID randomized trial, subjects from 
both arms were offered augmentation therapy in a two-year 
open label extension trial24. Both the group which received AAT 
augmentation therapy in the randomized trial (early-start) and 
the group which received placebo (delayed-start) showed the 
same rate of decline in lung density. However, subjects initially 
treated with placebo did not recover any of the lost lung density. 
The extension study showed that the effects of augmentation 
were sustained over four years and supported earlier treatment 
initiation.
Patients in RAPID with higher trough serum AAT levels dur-
ing treatment had less loss of lung density in a post-hoc analysis. 
A major reason for the increased levels was a greater infused 
dose of augmentation in patients with higher body weight5. This 
finding has motivated clinical trials of double dose weekly 
augmentation therapy25. Other therapies under investigation 
include inhaled AAT26 and gene therapy27. Based on the RAPID 
trial, augmentation therapy currently can be recommended in this 
targeted subgroup of patients with severe AAT deficiency and 
reduced lung function in a potentially modifiable range (e.g. FEV1 
35–70% predicted).
COPD risk in heterozygous carriers
Starting shortly after the discovery that severe AAT deficiency 
was associated with COPD28, there has been a debate regarding 
the risk of lung disease in PI MZ carriers. Most of the literature 
consisted of small case-control studies, many of which found an 
association. We performed a meta-analysis, finding an increased 
risk of COPD with a combined odds ratio (OR) of 2.31 (95% 
CI 1.60-3.35). The effect was attenuated in studies that adjusted 
for cigarette smoking (OR 1.61)29. However, population-based 
studies showed no difference in FEV1 between normal genotype 
(PI MM) and PI MZ individuals. These results were consistent 
with a small increase in COPD risk in all PI MZ heterozygotes or a 
larger risk in a subset.
Several pivotal studies have been published subsequently. 
Sørheim and colleagues examined PI MZ subjects in two large 
populations: the GenKOLS case-control study and the family- 
based International COPD Genetics Network (ICGN)30. In both 
studies, PI MZ heterozygotes had a reduced ratio of FEV1 to forced 
vital capacity (FVC) compared to PI MM (3.5% in GenKOLS, 
3.9% in ICGN). In GenKOLS, but not ICGN, PI MZ subjects had 
more emphysema on quantitative analysis of chest CT scans. There 
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Figure 1. The RAPID trial of augmentation therapy in severe alpha-1 antitrypsin deficiency. Intravenous augmentation therapy slowed the 
loss of lung density on chest CT scans over four years: (A) all subjects and (B) subjects completing the open-label extension study. Reprinted 
from 5, with permission from Elsevier.
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was no difference in COPD case-control status or in airway thick-
ness on chest CT in either study.
Molloy et al. performed a family-based study in Ireland6. 
They identified 51 PI MZ probands with COPD, and enrolled their 
family members. Comparing 99 PI MM and 89 PI MZ non-index 
relatives, PI MZ heterozygotes had reduced FEV1 and FEV1/FVC 
ratio compared to PI MM. In stratified analyses, this effect was 
strongest in ever-smokers and was not seen in never smokers. 
PI MZ was associated with an increased risk of COPD in all 
subjects (OR 5.18, 95% CI 1.27-21.15).
Within the COPDGene Study, a large U.S. cohort of current and 
former smokers with and without COPD, Foreman et al. performed 
genotyping for the SERPINA1 Z and S alleles7. Out of over 8000 
subjects, 261 PI MZ carriers were found, including 22 African 
Americans. Both white and African American PI MZ subjects had 
lower FEV1 and FEV1/FVC ratio compared to PI MM subjects. 
White PI MZ subjects had an increased risk of COPD (OR 1.42, 
95% CI 1.05-1.93) and more emphysema on quantitative analysis 
of chest CT scans (Figure 2). African American PI MZ subjects 
also had increased odds of COPD and increased CT emphysema, 
though the differences were not statistically significant, likely due 
to the small sample size.
In an abstract, Ortega et al. confirmed the association between 
PI MZ and reduced lung function and increased emphysema 
in the Subpopulations and Intermediate Outcome Measures in 
COPD Study (SPIROMICS)31. An exome genotyping array 
analysis of over 12,000 subjects also supported the association 
between PI MZ carriers and COPD32. These studies have clearly 
demonstrated that PI MZ carriers are at an increased risk for 
airflow obstruction and COPD, especially in current and former 
smokers. Molloy et al. did not show an increased risk in never 
smokers6; the other studies did not include enough never smokers 
to assess their risk.
The mechanisms for COPD risk in PI MZ subjects remain unde-
termined. Based on serum AAT levels in PI SS individuals, who 
are not at increased risk of COPD, and PI SZ individuals, who have 
an increased risk, a protective threshold of 11 µM (approximately 
55mg/dl) has been established9. However, serum AAT levels in 
PI MZ subjects remain above this threshold33.
Although the emphysema in severe AAT deficiency has tradition-
ally been attributed to the lack of inhibition of neutrophil elastase, 
there is increasing evidence that the Z protein itself may be 
deleterious in the lung. Accumulated Z-AAT produced in macro-
phages and lung epithelial cells leads to endoplasmic reticulum 
(ER) stress, which promotes inflammation, the unfolded protein 
response, and apoptosis34. Z-AAT in the extracellular space may 
act as a neutrophil chemoattractant35. A recent study of a Z-AAT 
transgenic mouse has supported the deleterious effect of the 
Z protein in the lungs36. These basic mechanisms have been 
studied in the context of ZZ models, but the Z protein may also 
have local deleterious effects in the PI MZ lung.
Figure 2. Lung function and chest CT imaging in PI MZ subjects in the COPD Gene Study. Non-Hispanic white subjects with PI MZ 
genotype had lower lung function and more emphysema and gas trapping on quantitative analysis of chest CT scans. FEV1 = forced 
expiratory volume in 1 second. HU = Hounsfield units. Reprinted from 7 with permission of the American Thoracic Society. Copyright © 2017 
American Thoracic Society. Annals of the American Thoracic Society is an official journal of the American Thoracic Society.
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Determining whether the increased COPD risk in PI MZ 
heterozygotes is due to low levels of AAT (loss of function) or due 
to the harmful effects of Z-AAT (toxic gain of function) could have 
therapeutic implications. In the former case, the concept of the 
protective threshold of 11 µM would have to be revisited, with 
perhaps different thresholds in current, former, and never smok-
ers. In the latter, PI MZ heterozygotes could be candidates for 
clinical trials of novel treatments, such as compounds targeting 
misfolded proteins or ER stress. Regardless of mechanism, identi-
fying PI MZ subjects has implications for risk assessment, family 
screening, and future precision medicine trials.
Clinical practice guidelines
The American Thoracic Society (ATS) first published clinical 
practice guidelines for the evaluation and treatment of patients 
with AAT deficiency in 198937. In collaboration with the European 
Respiratory Society (ERS), the ATS expanded and updated the 
guidelines in 200338. The Alpha-1 Foundation convened an expert 
panel, which reviewed the literature since 2002 and produced 
updated clinical practice guidelines, published in 20168.
The guidelines provide recommendations related to testing for 
AAT deficiency, evaluation of the patient with AAT deficiency, 
and treatment with intravenous augmentation therapy. The 
systematic review supports testing in all patients with COPD, as 
well as patients with other potential manifestations of AAT defi-
ciency, specifically unexplained chronic liver disease, unexplained 
bronchiectasis, necrotizing panniculitis, and granulomatosis 
with polyangiitis. Testing is also recommended for first-degree 
relatives of subjects with severe AAT deficiency. In addition 
to protein levels, genotyping of at least the S and Z alleles is 
recommended for initial testing.
Two of the more controversial recommendations relate to 
evaluation of the newly diagnosed patient with AAT deficiency, 
namely full pulmonary function testing (spirometry, lung volumes 
and diffusing capacity) and a baseline chest CT scan39. Chest 
CT scans are not currently recommended in the initial evalua-
tion of patients with COPD unrelated to AAT deficiency40,41. The 
recommendations for serial spirometry to follow lung function 
and annual liver testing with clinical exam, ultrasound and labo-
ratory studies are less controversial, although there is no clear 
consensus regarding the age to start liver evaluations42. Serial chest 
CT scans are not recommended.
Indications for augmentation therapy are largely congruent with 
the RAPID trial described above. There is a recommendation for 
discussion of augmentation therapy in patients with milder lung 
disease (FEV1 >65% predicted); declining diffusing capacity 
or emphysema progression on CT scan may help guide therapy 
in this situation. Augmentation therapy is not recommended in 
PI MZ carriers43.
Conclusions
COPD is a major cause of morbidity and mortality worldwide. 
Severe AAT deficiency may be responsible for 1–2% of COPD 
cases in populations of European descent44. Yet AAT deficiency 
remains under-diagnosed, due to inadequate awareness, lack of 
referral for appropriate testing, and possibly therapeutic nihil-
ism regarding COPD in general. Three developments in the past 
several years should provide additional imperatives for diagnosis. 
Updated clinical practice guidelines provide clear recommenda-
tions regarding diagnosis and management8. The RAPID trial has 
demonstrated the effectiveness of the augmentation therapy for 
AAT deficiency, with support for earlier initiation5. This fits 
squarely into the modern paradigm of precision medicine, with a 
diagnostic test to identify a subtype of a heterogeneous disease, 
namely COPD, leading to a targeted treatment45. And lastly, the 
demonstration of an increased risk of COPD in PI MZ carriers 
may have the broadest public health implications, since there may 
be over 6 million PI MZ carriers in the U.S. and over 27 million 
worldwide46. Improved recognition of the role of AAT deficiency 
in lung and liver disease is crucial for the clinical care of these 
patients and necessary for the development of novel therapies.
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